SYRE revenueFY2025$0
SYRE revenue was $0 for fiscal 2025 (ended Dec 31, 2025), compared with $0 in fiscal 2024.
Spyre Therapeutics Inc. (SYRE) financials
For fiscal 2025 (ended Dec 31, 2025), Spyre Therapeutics Inc. reported $0 of revenue and -$155.20M of net income.
- Revenue, FY2025
- $0
- Net income, FY2025
- -$155.20M
- Cash
- $82.73M
- Market cap
- $9.86B
FY2016FY2025
FY2016FY2025
FY2016FY2024
SYRE revenue and earnings growth
SYRE net incomeQ3 2026-$96.12M
SYRE net income was -$96.12M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$11.18M a year earlier. For the full fiscal 2025 it was -$155.20M, compared with -$208.02M in fiscal 2024.
SYRE EPSQ1 2026-$0.74
SYRE diluted EPS was -$0.74 in fiscal Q1 2026 (ended Mar 31, 2026). For the full fiscal 2023 it was $13.76.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886.0K | $2.33M | $18.74M | $0 | $0 | $3.89M | $5.21M | $4.63M |
| Research and development | $171.65M | $162.79M | $89.50M | $58.58M | $57.07M | $59.64M | $64.60M | $36.72M | $22.82M | $18.14M |
| Selling, general and admin | $47.91M | $45.78M | $39.95M | $28.53M | $27.32M | $21.84M | $15.73M | $12.63M | $10.07M | $8.39M |
| Operating income | -$209.56M | -$208.57M | -$242.30M | -$84.78M | -$65.65M | -$81.48M | -$80.33M | -$45.46M | -$27.68M | -$21.91M |
| Pre-tax income | -$155.22M | -$207.97M | -$338.82M | -$83.95M | -$65.66M | -$80.89M | -$78.25M | - | - | - |
| Income tax | -$15.0K | $51.0K | -$26.0K | -$136.0K | $141.0K | $0 | $0 | $0 | $0 | $0 |
| Net income | -$155.20M | -$208.02M | -$338.79M | -$83.81M | -$65.80M | -$80.89M | -$78.25M | -$44.35M | -$27.24M | -$21.70M |
| EPS, basic | - | - | $13.76 | -$24.86 | -$25.02 | -$38.00 | -$61.25 | -$53.25 | -$45.00 | -$55.50 |
| EPS, diluted | - | - | $13.76 | -$24.86 | -$25.02 | -$38.00 | -$61.25 | -$53.25 | -$45.00 | -$55.50 |
| Diluted shares | - | - | 6.9M | 3.4M | 2.6M | 2.1M | 1.3M | 832,902.4 | 605,127.68 | 391,669.12 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $85.72M | $89.42M | $188.89M | $36.42M | $16.98M | $91.94M | $19.25M | $22.46M | $12.82M | $47.75M |
| Short-term investments | - | - | - | - | - | - | - | $52.05M | $37.48M | $15.75M |
| Current assets | $777.78M | $608.47M | $341.53M | $62.26M | $98.89M | $149.79M | $74.50M | $76.67M | $54.99M | $66.42M |
| Total assets | $777.78M | $608.48M | $341.86M | $71.14M | $109.93M | $161.62M | $83.18M | $77.74M | $56.08M | $67.06M |
| Current liabilities | $58.69M | $54.06M | $31.98M | $14.66M | $20.14M | $16.44M | $18.36M | $10.24M | $5.63M | $3.96M |
| Total liabilities | $62.55M | $90.68M | $73.29M | $20.84M | $25.98M | $21.79M | $23.10M | $10.31M | $5.74M | $4.10M |
| Shareholders' equity | $715.24M | $517.80M | $184.02M | $50.30M | $83.94M | $139.83M | $60.08M | $67.43M | $50.34M | $62.97M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$169.25M | -$157.41M | -$99.91M | -$80.14M | -$53.72M | -$75.78M | -$65.69M | -$32.19M | -$24.61M | -$18.84M |
| Capital expenditures | - | $0 | $0 | $38.0K | $573.0K | $4.28M | $1.49M | $422.0K | $619.0K | $212.0K |
| Free cash flow | - | -$157.41M | -$99.91M | -$80.18M | -$54.29M | -$80.06M | -$67.18M | -$32.62M | -$25.23M | -$19.05M |
| Investing cash flow | -$143.47M | -$353.29M | -$108.39M | $57.01M | -$22.62M | -$7.60M | -$1.74M | -$15.23M | -$22.53M | -$12.08M |
| Financing cash flow | $309.02M | $410.91M | $361.08M | $42.68M | $1.39M | $154.51M | $65.72M | $57.07M | $12.21M | $49.37M |
| Stock-based compensation | $37.61M | $44.83M | $25.68M | $7.11M | $8.04M | $6.26M | $4.88M | $4.28M | $2.49M | $1.22M |
| Depreciation and amortization | $0 | $0 | $744.0K | $1.57M | $1.58M | $996.0K | $418.0K | $293.0K | $249.0K | $132.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | -100.0% | -62.0% | -87.6% | - | - | -100.0% | -25.3% | 12.5% | - |
| Operating margin | - | - | -27348.0% | -3640.2% | -350.3% | - | - | -1169.3% | -531.7% | -473.3% |
| Net margin | - | - | -38238.1% | -3598.8% | -351.1% | - | - | -1140.6% | -523.3% | -468.8% |
| Free cash flow margin | - | - | -11276.5% | -3442.8% | -289.7% | - | - | -838.9% | -484.8% | -411.7% |
| Return on equity | -21.7% | -40.2% | -184.1% | -166.6% | -78.4% | -57.9% | -130.2% | -65.8% | -54.1% | -34.5% |
| Return on assets | -20.0% | -34.2% | -99.1% | -117.8% | -59.9% | -50.1% | -94.1% | -57.0% | -48.6% | -32.4% |
| Current ratio | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 | 9.11 | 4.06 | 7.49 | 9.77 | 16.75 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $0 |
| Research and development | $89.17M | $65.50M | $60.41M | $44.64M | $45.25M | $40.15M | $41.62M | $50.48M | $44.74M | $32.64M | $34.93M | $33.68M |
| Selling, general and admin | $16.55M | $16.14M | $15.23M | $12.53M | $11.64M | $11.79M | $11.94M | $10.77M | $10.65M | $11.51M | $12.85M | $14.07M |
| Operating income | -$105.72M | -$41.64M | -$45.64M | -$57.17M | -$56.89M | -$41.94M | -$53.57M | -$61.25M | -$55.39M | -$44.15M | -$47.77M | -$45.91M |
| Pre-tax income | -$96.12M | -$36.20M | -$69.00M | -$62.53M | -$11.18M | -$36.72M | -$44.79M | -$56.30M | -$69.01M | -$38.84M | -$43.83M | -$63.18M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | -$15.0K | $1.0K | $18.0K | $0 | $32.0K | $0 |
| Net income | -$96.12M | -$36.20M | -$69.00M | -$62.53M | -$11.18M | -$36.72M | -$44.77M | -$56.30M | -$69.03M | -$38.84M | -$43.86M | -$63.18M |
| EPS, basic | - | - | - | - | - | - | - | - | $1.06 | $0.59 | $0.72 | - |
| EPS, diluted | - | - | -$0.74 | - | - | - | - | - | $1.06 | $0.59 | $0.72 | - |
| Diluted shares | - | - | - | - | - | - | - | - | 50.9M | 45.3M | 36.5M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $82.73M | $162.01M | $97.19M | $85.72M | $64.90M | $81.66M | $48.49M | $89.42M | $71.58M | $45.14M | $227.55M | $188.89M |
| Current assets | $1.10B | $1.17B | $763.95M | $777.78M | $504.60M | $538.83M | $569.77M | $608.47M | $421.08M | $435.74M | $487.27M | $341.53M |
| Total assets | $1.10B | $1.17B | $763.95M | $777.78M | $504.60M | $538.83M | $569.78M | $608.48M | $421.09M | $436.07M | $487.60M | $341.86M |
| Current liabilities | $40.14M | $63.30M | $85.16M | $58.69M | $46.27M | $83.06M | $70.68M | $54.06M | $57.54M | $22.12M | $42.82M | $31.98M |
| Total liabilities | $48.19M | $71.86M | $93.14M | $62.55M | $49.50M | $83.06M | $87.17M | $90.68M | $93.70M | $61.68M | $81.93M | $73.29M |
| Shareholders' equity | $1.05B | $1.10B | $670.81M | $715.24M | $455.10M | $455.77M | $482.61M | $517.80M | $327.39M | $374.38M | $152.27M | $184.02M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$77.50M | -$69.88M | -$57.37M | -$44.58M | -$37.12M | -$46.56M | -$40.99M | -$37.20M | -$29.42M | -$62.25M | -$28.54M | -$31.04M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | - | -$31.04M |
| Investing cash flow | -$3.80M | -$297.90M | $56.58M | -$247.41M | $25.00M | $79.00M | -$61.0K | -$170.54M | $42.74M | -$120.52M | -$104.96M | -$35.27M |
| Financing cash flow | $2.02M | $432.60M | $12.26M | $312.81M | -$4.64M | $731.0K | $125.0K | $225.60M | $12.78M | $360.0K | $172.16M | $163.61M |
| Stock-based compensation | $14.17M | $13.51M | $12.81M | $9.81M | $9.57M | $9.38M | $8.86M | $9.22M | $13.10M | $8.70M | $13.84M | $17.27M |
| Depreciation and amortization | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $0 |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | -100.0% | -100.0% | -100.0% |
| Current ratio | 27.40 | 18.53 | 8.97 | 13.25 | 10.90 | 6.49 | 8.06 | 11.26 | 7.32 | 19.70 | 11.38 | 10.68 |
Source: XBRL data Spyre Therapeutics Inc. files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Nov 9, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
SYRE peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SYRE | $0 | - | -$155.20M | - | $9.86B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
SYRE FAQ
5 questionsWhat is SYRE revenue?
Spyre Therapeutics Inc. (SYRE) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025).Is SYRE profitable?
No. Spyre Therapeutics Inc. reported a net loss of $155.20M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does SYRE have?
Spyre Therapeutics Inc. reported $82.73M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did SYRE last report financial results?
The latest statements here come from Spyre Therapeutics Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.Where does this SYRE financial data come from?
Quantisnow builds these statements from the structured XBRL data Spyre Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.